ARTICLE | Emerging Company Profile
Vigil: restoring the vigilance of microglia
Emerging Company Profile: After debuting with $50M, Atlas’ Vigil plans to pursue rare microgliopathies with assets from Amgen
December 17, 2020 2:44 PM UTC
Incubated by Atlas Venture and led by former Ipsen CBO Ivana Magovčević-Liebisch, Vigil launched last week with $50 million in series A financing to advance two TREM2 agonists in-licensed from Amgen in rare microgliopathy indications.
“We’ve been interested in neuroinflammation for years,” Atlas’ Bruce Booth told BioCentury. “TREM2 came up as a really important node” in various neurodegenerative disorders...